2008
DOI: 10.1590/s1807-59322008000600009
|View full text |Cite
|
Sign up to set email alerts
|

Pretreatment Tumor Volume Estimation Based on Total Serum PSA in Patients with Localized Prostate Cancer

Abstract: Kato RB, Srougi V, Salvadori FA, Ayres PPMR, Leite KM, Srougi M. Pretreatment tumor volume estimation based on total serum PSA in patients with localized prostate cancer. Clinics. 2008;63:759-62. OBJECTIVES:To establish a formula that estimates tumor volume in localized prostate cancer based on serum prostate specific antigen levels. One of the main prognostic variables in localized prostate cancer is tumor volume, which can be precisely defined only after prostate extirpation. The present study defines a simp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
10
0

Year Published

2010
2010
2020
2020

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 17 publications
(11 citation statements)
references
References 16 publications
1
10
0
Order By: Relevance
“…In cases with high tumor volume, lymphovascular invasion and intraductal spread of carcinoma were frequently seen as well. Tumor volume correlates well with serum PSA levels, 30 which is consistent with our finding demonstrating the 50% difference in mean preoperative PSA levels between the 2 groups (12.2 ng/mL versus 8.1 ng/mL). By itself, a high level of preoperative PSA is associated with higher risk of LN þ .…”
Section: Commentsupporting
confidence: 91%
“…In cases with high tumor volume, lymphovascular invasion and intraductal spread of carcinoma were frequently seen as well. Tumor volume correlates well with serum PSA levels, 30 which is consistent with our finding demonstrating the 50% difference in mean preoperative PSA levels between the 2 groups (12.2 ng/mL versus 8.1 ng/mL). By itself, a high level of preoperative PSA is associated with higher risk of LN þ .…”
Section: Commentsupporting
confidence: 91%
“…A general indicator of possible relapse is an increasing concentration of prostate-specific antigen (PSA) in the blood. PSA is generally regarded as a good biomarker for disease progression in primary PCa, and it is a well-studied surrogate of tumor burden [ 1 4 ]. However, at an early PCa recurrence or microscopic metastatic spread, PSA alone can seldom be used for staging and is generally associated with relatively low levels of serum PSA concentrations (< 0.2 ng/ml).…”
Section: Introductionmentioning
confidence: 99%
“…Previously Kato et al (12) related that PSA level is proportional to prostate tumor volume, and since all cases selected had localized disease, PSA tend to be in the same range in both groups. Staging was a pre-selection variable, justifying the similarities between the two groups.…”
Section: Discussionmentioning
confidence: 90%